AQUALIS:QoL of CLL patients treated with acalabrutinib in France, retrospective study based on data from PLATON database - AQUALIS

Study identifier:D8220R00057

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

AQUALIS: Quality of life of patients with chronic lymphocytic leukemia treated with acalabrutinib in France: a retrospective observational study based on data extracted from the PLATON database

Medical condition

Chronic Lymphocytic Leukemia

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

120

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 30 Sept 2024
Estimated Primary Completion Date: 31 Dec 2025
Estimated Study Completion Date: 31 Dec 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Hospitalidee, Hospitalidee has been asserted to be a valid organization name by UHToulouse

Inclusion and exclusion criteria